Biocartis & Merck lay focus on improving colorectal cancer treatment in Middle East
Idylla KRAS Mutation test and Idylla NRAS-BRAF Mutation test rapidly determine the RAS biomarker status Belgium headquartered firm Biocartis has announced an expansion of its collaboration with Merck Serono Middle East and Merck Saudi, both affiliates of …